AEON Biopharma gets FDA Type 2b feedback on ABP-450 biosimilar path, files CMAP INDNov 16Quarterly updateAEON Biopharma, Inc.
AEON gets FDA Type 2b feedback on ABP-450 biosimilar pathway for BOTOXSep 30Regulatory milestoneAEON Biopharma, Inc.onabotulinumtoxina
AEON Biopharma reports Q2 2026 results, cites new financing and FDA meeting on ABP-450Aug 12Quarterly updateAEON Biopharma, Inc.
AEON Biopharma closes $13.75 million offering with attached milestone warrantsJul 15FinancingAEON Biopharma, Inc.